Category: Pharmaceuticals
Pharmaceuticals market research reports by DelveInsight
-
Gaucher's disease - Pipeline Insight, 2025
DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 14+ companies and 16+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therape ... Read More
-
Liver Cirrhosis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights The Liver Cirrhosis market size in the 7MM was nearly USD 3,100 million in 2023, which is further anticipated to increase with a siginificant CAGR during the forecast period from (2024-2034). Liver cirrhosis is a chronic and progressive liver disease characterized by the replacement o ... Read More
-
Bullous Keratopathy - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s estimates, in 2023, there were approximately 192 thousand diagnosed Bullous Keratopathy prevalent cases in the 7MM. Of these, the United States accounted for 41% of the cases, while Germany and Japan represented 13% and 9% of the cases, respectively. The bu ... Read More
-
Multiple Myeloma - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights The total market size in the 7MM for multiple myeloma was estimated to be nearly USD 21,300 million in 2023, which is expected to show positive growth by 2034, owing to rise in incident cases, label expansion and penetration of current therapies in earlier lines, high adoption of newe ... Read More
-
IgG4-Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights IgG4-RD can affect virtually any organ, with common presentations including the pancreas, bile ducts, salivary glands, lacrimal glands, orbits, kidneys, lungs, and retroperitoneum. The true prevalence of IgG4-RD is unknown. Given its relatively recent discovery, lack of widespread rec ... Read More
-
Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s estimates, in 2023, there were approximately 191,589 diagnosed prevalent cases of idiopathic inflammatory myositis in the 7MM. Of these, the United States accounted for 48% of the cases, while EU4 and the UK accounted for nearly 38% and Japan represented 14 ... Read More
-
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights The Ulcerative Colitis Market Size in the 7MM was around USD 8,400 Million in 2023. The Ulcerative Colitis Market is anticipated to witness a positive shift owing to better uptake of existing drugs, and raised awareness. Ulcerative Colitis treatment is complex and comprises the use of ... Read More
-
Sickle Cell Disease (SCD) - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of abnormal hemoglobin, causing red blood cells to become sickle-shaped. SCD is a global health concern, particularly prevalent in populations with African, Middle Eastern, Mediterranean, and South Asi ... Read More
-
50S Ribosomal Subunit (50S RNA) Inhibitor - Pipeline Insight, 2025
“50S Ribosomal Subunit (50S RNA) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 50S Ribosomal Subunit (50S RNA) Inhibitor development. The report provides detailed coverage ... Read More
-
5-HT2 Antagonist - Pipeline Insight, 2025
“5-HT2 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT2 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ... Read More
-
5-HT4 Partial Agonist - Pipeline Insight, 2025
“5-HT4 Partial Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Partial Agonist development. The report provides detailed coverage of the pipeline landscape for this mech ... Read More
-
Adenosine A2B Receptor Antagonist - Pipeline Insight, 2025
“Adenosine A2B Receptor Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2B Receptor Antagonist development. The report provides detailed coverage of the pipeline ... Read More
-
Alpha Glucosidase Inhibitor - Pipeline Insight, 2025
“Alpha Glucosidase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha Glucosidase Inhibitor development. The report provides detailed coverage of the pipeline landscape f ... Read More
-
Alpha Receptor Agonist - Pipeline Insight, 2025
“Alpha Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this me ... Read More
-
Alpha-1 Agonist - Pipeline Insight, 2025
“Alpha-1 Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha-1 Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of act ... Read More
-
Alpha v Beta 5 Integrin Antagonist - Pipeline Insight, 2025
“Alpha v Beta 5 Integrin Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alpha v Beta 5 Integrin Antagonist development. The report provides detailed coverage of the pipeli ... Read More
-
Androgen Antagonist - Pipeline Insight, 2025
“Androgen Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Androgen Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanis ... Read More
-
Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2025
“Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiotensin Converting Enzyme (ACE) Inhibitor development. The report provides detailed ... Read More
-
Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2025
“Angiopoietin 2 (Ang-2) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Angiopoietin 2 (Ang-2) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Endothelin Receptor Antagonist - Pipeline Insight, 2025
DelveInsight’s, “Endothelin Receptor Antagonist - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Endothelin Receptor Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. ... Read More
-
G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2025
“G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across G-Protein Coupled Receptor (GPCR) Agonist development. The report provides detailed coverage ... Read More
-
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025
DelveInsight’s, “Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 10 pipeline drugs in Interleukin-2 (IL-2) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s - Pipeline Insight, 2025
“Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s development. The ... Read More
-
Selective COX-2 Inhibitor - Pipeline Insight, 2025
“Selective COX-2 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Selective COX-2 Inhibitor development. The report provides detailed coverage of the pipeline landscape for t ... Read More
-
TGF-Beta-2 Inhibitor - Pipeline Insight, 2025
“TGF-Beta-2 Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across TGF-Beta-2 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechan ... Read More
Research Assistance
